UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia

Leukemia, 2013-06, Vol.27 (6), p.1254-1262

2013

Volltextzugriff (PDF)

Patient preferences for palliative treatment of locally advanced or metastatic gastric cancer and adenocarcinoma of the gastroesophageal junction: a choice-based conjoint analysis study from Germany

BMC cancer, 2016-12, Vol.16 (1), p.937-937, Article 937

2016

Volltextzugriff (PDF)

A heuristic algorithm for a single vehicle static bike sharing rebalancing problem

Computers & operations research, 2017-03, Vol.79, p.19-33

2017

Volltextzugriff (PDF)

1503TiP A phase II study of cemiplimab plus BNT116 versus cemiplimab alone in first-line treatment of patients with advanced non-small cell lung cancer with PD-L1 expression ≥50

Annals of oncology, 2023-10, Vol.34, p.S846-S846

2023

Volltextzugriff (PDF)

Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia

Leukemia, 2012-07, Vol.26 (7), p.1475-1481

2012

Volltextzugriff (PDF)

1196TiP LuCa-MERIT-1: First-in-human, open label, phase I dose confirmation trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer

Annals of oncology, 2022-09, Vol.33, p.S1095

2022

Volltextzugriff (PDF)

Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph ALL) during imatinib treatment

Leukemia, 2003-09, Vol.17 (9), p.1700-1706

2003

Volltextzugriff (PDF)

Reichsgesetz über den Versicherungsvertrag: Nebst dem zugehörigen Einführungsgesetze. Vom 30. Mai 1908

3., neubearb. Aufl. Reprint 2018 edition., 2019

Volltextzugriff (PDF)

Non-Elementary Formulations for Single Vehicle Routing Problems with Pickups and Deliveries

Operations research, 2017-11, Vol.65 (6), p.1597-1614

2017

Volltextzugriff (PDF)

Minimizing CO2 emissions in a practical daily carpooling problem

Computers & operations research, 2017-05, Vol.81, p.40-50

2017

Volltextzugriff (PDF)

The Static Bike Sharing Rebalancing Problem with Forbidden Temporary Operations

Transportation science, 2019-05, Vol.53 (3), p.882-896

2019

Volltextzugriff (PDF)

Nonsecretory primary plasma cell leukemia with good response to thalidomide-based treatment

International journal of hematology, 2007-07, Vol.86 (1), p.66-68

2007

Volltextzugriff (PDF)

A practical time slot management and routing problem for attended home services

Omega (Oxford), 2018-12, Vol.81, p.208-219

2018

Volltextzugriff (PDF)

PD-008 Adding ramucirumab to second-line irinotecan, 5-fluorouracil and folinic acid (FOLFIRI) treatment for metastatic colorectal carcinoma (mCRC): resource utilization data from RAISE, a global, randomized, double-blind, multicenter phase 3 study

Annals of oncology, 2016-06, Vol.27, p.ii104

2016

Volltextzugriff (PDF)

PCN1 - Adding Ramucirumab To Second-Line Irinotecan, 5-Fluorouracil and Folinic Acid (Folfiri) Treatment for Metastatic Colorectal Carcinoma (Mcrc): Resource Utilization Data from Raise, A Global, Randomized, Double-Blind, Multicenter Phase 3 Study

Value in health, 2017-10, Vol.20 (9), p.A871-A871

2017

Volltextzugriff (PDF)

Adding Ramucirumab To Second-Line Irinotecan, 5-Fluorouracil and Folinic Acid (Folfiri) Treatment for Metastatic Colorectal Carcinoma (Mcrc): Resource Utilization Data from Raise, A Global, Randomized, Double-Blind, Multicenter Phase 3 Study

Value in health, 2017-10, Vol.20 (9), p.A871

2017

Volltextzugriff (PDF)

155P BNT113 + pembrolizumab as first-line treatment in patients with unresectable recurrent/metastatic HNSCC: Preliminary safety data from AHEAD-MERIT

Immuno-oncology technology, 2022-12, Vol.16, p.100267, Article 100267

2022

Volltextzugriff (PDF)

Integrated inbound train split and load planning in an intermodal railway terminal

Transportation research. Part B: methodological, 2021-03, Vol.145, p.270-289

2021

Volltextzugriff (PDF)

A Retrospective Observational Study of the Epidemiology of Advanced Gastric Cancer in Germany

Gesundheitsökonomie & Qualitätsmanagement, 2014-09, Vol.20 (3), p.108-113

2014

Volltextzugriff (PDF)

Aggregated formulations, exact and heuristic algorithms for pickup and delivery routing problems

4OR, 2018-12, Vol.16 (4), p.447-448

Bruck, Bruno P.

2018

Volltextzugriff (PDF)

Moderne Ernährungstherapie bei onkologischen Patienten – ein Positionspapier

Aktuelle Ernährungsmedizin, 2014-04, Vol.39 (2), p.127-131

2014

Volltextzugriff (PDF)

Zweitlinientherapie mit Ramucirumab plus Irinotecan, 5-Fluorouracil und Folinsäure (FOLFIRI) bei metastasiertem Kolorektalkarzinom (mCRC) nach Progression mit Bevacizumab plus Oxaliplatin und Fluoropyrimidin: Ergebnisse der randomisierten, plazebokontrollierten Phase-III-Doppelblindstudie RAISE

Zeitschrift für Gastroenterologie, 2016-08, Vol.54 (8)

2016

Volltextzugriff (PDF)

Ordovician and Silurian acritarch assemblages from the west Leinster and Slievenamon areas of southeast Ireland

Review of palaeobotany and palynology, 2000-12, Vol.113 (1), p.57-71

2000

Volltextzugriff (PDF)

PD-008Adding ramucirumab to second-line irinotecan, 5-fluorouracil and folinic acid (FOLFIRI) treatment for metastatic colorectal carcinoma (mCRC): resource utilization data from RAISE, a global, randomized, double-blind, multicenter phase 3 study

Annals of oncology, 2016-06, Vol.27 (suppl_2), p.ii104-ii104

2016

Volltextzugriff (PDF)

Management of Neisseria gonorrhoeae infection over 12 months in a genitourinary medicine setting against British Association for Sexual Health and HIV auditable outcome measures

International journal of STD & AIDS, 2012-03, Vol.23 (3), p.e30-e32

2012

Volltextzugriff (PDF)

1 – 25 von 1.111

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(858)
Mit Volltextzugriff
(954)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(563)
Physical Sciences
(253)
Life Sciences & Biomedicine
(231)
Physics
(231)
Humans
(184)
Technology
(176)
Exact Sciences And Technology
(139)
Materials Science
(105)
Female
(104)
Male
(101)
Condensed Matter: Electronic Structure, Electrical, Magnetic, And Optical Properties
(93)
Magnetic Properties And Materials
(89)
Materials Science, Multidisciplinary
(89)
Physics, Condensed Matter
(78)
Biological And Medical Sciences
(77)
Adult
(72)
Chemistry
(71)
Applied Sciences
(65)
Middle Aged
(64)
Engineering
(58)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia

Patient preferences for palliative treatment of locally advanced or metastatic gastric cancer and adenocarcinoma of the gastroesophageal junction: a choice-based conjoint analysis study from Germany

A heuristic algorithm for a single vehicle static bike sharing rebalancing problem

1503TiP A phase II study of cemiplimab plus BNT116 versus cemiplimab alone in first-line treatment of patients with advanced non-small cell lung cancer with PD-L1 expression ≥50

Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia

1196TiP LuCa-MERIT-1: First-in-human, open label, phase I dose confirmation trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer

Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph ALL) during imatinib treatment

Reichsgesetz über den Versicherungsvertrag: Nebst dem zugehörigen Einführungsgesetze. Vom 30. Mai 1908

Non-Elementary Formulations for Single Vehicle Routing Problems with Pickups and Deliveries

Minimizing CO2 emissions in a practical daily carpooling problem

The Static Bike Sharing Rebalancing Problem with Forbidden Temporary Operations

Nonsecretory primary plasma cell leukemia with good response to thalidomide-based treatment

A practical time slot management and routing problem for attended home services

PD-008 Adding ramucirumab to second-line irinotecan, 5-fluorouracil and folinic acid (FOLFIRI) treatment for metastatic colorectal carcinoma (mCRC): resource utilization data from RAISE, a global, randomized, double-blind, multicenter phase 3 study

PCN1 - Adding Ramucirumab To Second-Line Irinotecan, 5-Fluorouracil and Folinic Acid (Folfiri) Treatment for Metastatic Colorectal Carcinoma (Mcrc): Resource Utilization Data from Raise, A Global, Randomized, Double-Blind, Multicenter Phase 3 Study

Adding Ramucirumab To Second-Line Irinotecan, 5-Fluorouracil and Folinic Acid (Folfiri) Treatment for Metastatic Colorectal Carcinoma (Mcrc): Resource Utilization Data from Raise, A Global, Randomized, Double-Blind, Multicenter Phase 3 Study

155P BNT113 + pembrolizumab as first-line treatment in patients with unresectable recurrent/metastatic HNSCC: Preliminary safety data from AHEAD-MERIT

Integrated inbound train split and load planning in an intermodal railway terminal

A Retrospective Observational Study of the Epidemiology of Advanced Gastric Cancer in Germany

Aggregated formulations, exact and heuristic algorithms for pickup and delivery routing problems

Moderne Ernährungstherapie bei onkologischen Patienten – ein Positionspapier

Zweitlinientherapie mit Ramucirumab plus Irinotecan, 5-Fluorouracil und Folinsäure (FOLFIRI) bei metastasiertem Kolorektalkarzinom (mCRC) nach Progression mit Bevacizumab plus Oxaliplatin und Fluoropyrimidin: Ergebnisse der randomisierten, plazebokontrollierten Phase-III-Doppelblindstudie RAISE

Ordovician and Silurian acritarch assemblages from the west Leinster and Slievenamon areas of southeast Ireland

PD-008Adding ramucirumab to second-line irinotecan, 5-fluorouracil and folinic acid (FOLFIRI) treatment for metastatic colorectal carcinoma (mCRC): resource utilization data from RAISE, a global, randomized, double-blind, multicenter phase 3 study

Management of Neisseria gonorrhoeae infection over 12 months in a genitourinary medicine setting against British Association for Sexual Health and HIV auditable outcome measures

Suchergebnisse filtern